---
title: "Liquidia added to S&P SmallCap 600 ahead of June 22 trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289100240.md"
description: "Liquidia Corp (LQDA) will be added to the S&P SmallCap 600 index effective before market open on June 22, 2026. The inclusion, based on criteria such as market cap and profitability, reflects the company's operational progress and aims to enhance its visibility among investors. Liquidia focuses on therapies for respiratory and vascular diseases using its PRINT technology."
datetime: "2026-06-08T20:33:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289100240.md)
  - [en](https://longbridge.com/en/news/289100240.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289100240.md)
---

# Liquidia added to S&P SmallCap 600 ahead of June 22 trading

**Liquidia will be added to the S&P SmallCap 600, effective before the open on June 22, 2026.**

**Key Highlights:**

-   SEC Form 8-K reports inclusion in the S&P SmallCap 600 effective prior to market open June 22, 2026.
-   S&P SmallCap 600 selection based on market cap, liquidity, public float and profitability criteria.
-   Company says inclusion reflects operational progress and may enhance visibility in the investment community.
-   Press release reiterates Liquidia’s focus on therapies for respiratory and vascular diseases and its PRINT technology.

Original SEC Filing: Liquidia Corp \[ LQDA \] - 8-K - Jun. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)

## Related News & Research

- [Major Insider Move at Liquidia Technologies Shakes Up Investor Watchlists](https://longbridge.com/en/news/289405446.md)
- [Insider Selling: Stephen M Bloch Unloads $14.27M Of Liquidia Stock](https://longbridge.com/en/news/289486314.md)
- [08:00 ETApnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea](https://longbridge.com/en/news/289322957.md)
- [MBX Biosciences Highlights Sustained Calcium Control In Rare Disease](https://longbridge.com/en/news/289614050.md)
- [Summit Therapeutics withdraws proposed underwritten offering citing market conditions](https://longbridge.com/en/news/289460448.md)